8 reasons for using ambroxol in respiratory treatment Review article
Article Sidebar
Published:
Mar 31, 2016
Keywords:
mucolytics, mucokinetics, ambroxol, COPD
Main Article Content
Abstract
Mucolytics and their mechanisms of action are a source of diverse concerns on the part of patients and doctors alike. Some of us believe them to be very important in the treatment of many diseases, while others are sceptical as to their indications and possibilities of use. According to some, they may lead to an excessive production of secretion, whereas others claim that mechanism to be a well-grounded one. In some conditions, mucolytics are not administered at all, while in other cases they are applied with great conviction by a great many specialists. Nevertheless, they are not always administered in compliance with the current guidelines or clinical studies. In an attempt to address those reservations, the present brief review discusses the use of a triple-action drug – ambroxol.
Article Details
How to Cite
Pawliczak, R. (2016). 8 reasons for using ambroxol in respiratory treatment. Medycyna Faktow (J EBM), 9(1(30), 51-54. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2270
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Stetinova V, Herout V, Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med 2004; 4(3): 152-158.
2. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92(4): 609-623.
3. Wiessmann KJ, Niemeyer K. [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author’s transl.)]. Arzneimittelforschung 1978; 28(5a): 918-921.
4. Wu X, Li S, Zhang J et al. Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. J Clin Pharmacol 2014; 54(11): 1199-1206.
5. Gibbs BF, Wolff HH, Grabbe J. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res 1999; 48(2): 86-93.
6. Paleari D, Rossi GA, Nicolini G et al. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov 2011; 6(11): 1203-1214.
7. Peroni DG, Moser S, Gallo G et al. Ambroxol inhibits neutrophil respiratory burst activated by alpha chain integrin adhesion. Int J Immunopathol Pharmacol 2013; 26(4): 883-887.
8. Nowak D, Antczak A, Krol M et al. Antioxidant properties of Ambroxol. Free Radic Biol Med 1994; 16(4): 517-522.
9. Nowak D, Antczak A, Pietras T et al. Protective effect of ambroxol against heat- and hydrogen peroxide-induced damage to lung lipids in mice. Eur Respir J 1994; 7(9): 1629-1634.
10. Nowak D, Pierscinski G, Drzewoski J. Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Free Radic Biol Med 1995; 19(5): 659-663.
11. Nowak D, Pietras T, Antczak A. Ambroxol inhibits endotoxin-induced lipid peroxidation in mice. Pol J Pharmacol 1993; 45(3): 317-322.
12. Gao X, Huang Y, Han Y et al. The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch Med Sci 2011; 7(3): 405-413.
13. Yamaya M, Nishimura H, Nadine LK et al. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res 2014; 37(4): 520-529.
14. Beeh KM, Beier J, Esperester A et al. Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13(12): 557-562.
15. Passali D, Zavattini G. Multicenter study on the treatment of secretory otitis media with ambroxol. Importance of a surface-tension-lowering substance. Respiration 1987; 51(supl. 1): 52-59.
16. Schulz M, Hammerlein A, Hinkel U et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. Int J Clin Pharmacol Ther 2006; 44(9): 409-421.
17. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4(8): 1119-1129.
18. Paganin F, Bouvet O, Chanez P et al. Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Biopharm Drug Dispos 1995; 16(5): 393-401.
19. Teramoto S, Suzuki M, Ohga M et al. Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary diseases. Pharmacology 1999; 59(3): 135-141.
20. Jahnz-Rozyk K, Kucharczyk A, Chcialowski A et al. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients]. Pol Merkur Lekarski 2001; 11(63): 239-243.
21. Nowak D. [Antioxidative features of ambroxol – usefulness in COPD]. Pneumonol Alergol Pol 2001; 69(9-10): 590-593.
22. Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17(1): 27-34.
23. Yamada T, Takemura Y, Niisato N et al. Action of N-acylated ambroxol derivatives on secretion of chloride ions in human airway epithelia. Biochem Biophys Res Commun 2009; 380(3): 586-590.
24. Macchi A, Terranova P, Castelnuovo P. Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy. Int J Immunopathol Pharmacol 2012; 25(1): 207-217.
25. Lu Q, Yu J, Yang X et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int J Antimicrob Agents 2010; 36(3): 211-215.
26. Lu Q, Yu J, Bao L et al. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model. Chemotherapy 2013; 59(1): 51-56.
27. Rene HD, Jose MS, Isela SN et al. Effects of ambroxol on Candida albicans growth and biofilm formation. Mycoses 2014; 57(4): 228-232.
2. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92(4): 609-623.
3. Wiessmann KJ, Niemeyer K. [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author’s transl.)]. Arzneimittelforschung 1978; 28(5a): 918-921.
4. Wu X, Li S, Zhang J et al. Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. J Clin Pharmacol 2014; 54(11): 1199-1206.
5. Gibbs BF, Wolff HH, Grabbe J. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res 1999; 48(2): 86-93.
6. Paleari D, Rossi GA, Nicolini G et al. Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood. Expert Opin Drug Discov 2011; 6(11): 1203-1214.
7. Peroni DG, Moser S, Gallo G et al. Ambroxol inhibits neutrophil respiratory burst activated by alpha chain integrin adhesion. Int J Immunopathol Pharmacol 2013; 26(4): 883-887.
8. Nowak D, Antczak A, Krol M et al. Antioxidant properties of Ambroxol. Free Radic Biol Med 1994; 16(4): 517-522.
9. Nowak D, Antczak A, Pietras T et al. Protective effect of ambroxol against heat- and hydrogen peroxide-induced damage to lung lipids in mice. Eur Respir J 1994; 7(9): 1629-1634.
10. Nowak D, Pierscinski G, Drzewoski J. Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Free Radic Biol Med 1995; 19(5): 659-663.
11. Nowak D, Pietras T, Antczak A. Ambroxol inhibits endotoxin-induced lipid peroxidation in mice. Pol J Pharmacol 1993; 45(3): 317-322.
12. Gao X, Huang Y, Han Y et al. The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch Med Sci 2011; 7(3): 405-413.
13. Yamaya M, Nishimura H, Nadine LK et al. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res 2014; 37(4): 520-529.
14. Beeh KM, Beier J, Esperester A et al. Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13(12): 557-562.
15. Passali D, Zavattini G. Multicenter study on the treatment of secretory otitis media with ambroxol. Importance of a surface-tension-lowering substance. Respiration 1987; 51(supl. 1): 52-59.
16. Schulz M, Hammerlein A, Hinkel U et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. Int J Clin Pharmacol Ther 2006; 44(9): 409-421.
17. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4(8): 1119-1129.
18. Paganin F, Bouvet O, Chanez P et al. Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Biopharm Drug Dispos 1995; 16(5): 393-401.
19. Teramoto S, Suzuki M, Ohga M et al. Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or without chronic obstructive pulmonary diseases. Pharmacology 1999; 59(3): 135-141.
20. Jahnz-Rozyk K, Kucharczyk A, Chcialowski A et al. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients]. Pol Merkur Lekarski 2001; 11(63): 239-243.
21. Nowak D. [Antioxidative features of ambroxol – usefulness in COPD]. Pneumonol Alergol Pol 2001; 69(9-10): 590-593.
22. Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17(1): 27-34.
23. Yamada T, Takemura Y, Niisato N et al. Action of N-acylated ambroxol derivatives on secretion of chloride ions in human airway epithelia. Biochem Biophys Res Commun 2009; 380(3): 586-590.
24. Macchi A, Terranova P, Castelnuovo P. Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy. Int J Immunopathol Pharmacol 2012; 25(1): 207-217.
25. Lu Q, Yu J, Yang X et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int J Antimicrob Agents 2010; 36(3): 211-215.
26. Lu Q, Yu J, Bao L et al. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model. Chemotherapy 2013; 59(1): 51-56.
27. Rene HD, Jose MS, Isela SN et al. Effects of ambroxol on Candida albicans growth and biofilm formation. Mycoses 2014; 57(4): 228-232.